Published in J Pharm Biomed Anal on July 20, 2007
Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis (2012) 1.26
Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J (2011) 1.20
Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis (2011) 1.13
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J (2011) 1.03
A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights (2010) 0.97
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol (2015) 0.96
Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis (2012) 0.91
Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis. Antimicrob Agents Chemother (2014) 0.85
HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection. Antimicrob Agents Chemother (2013) 0.82
Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine. Am J Trop Med Hyg (2012) 0.78
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis (2016) 0.75
Malaria eradication on islands. Lancet (2000) 3.51
Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med (1984) 3.49
Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proc Natl Acad Sci U S A (1984) 2.52
Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg (2001) 2.34
Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma. J Chromatogr (1983) 2.28
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Chloroquine-resistant falciparum malaria in Madagascar and Kenya. Ann Trop Med Parasitol (1981) 2.03
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis (1999) 1.81
High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop (2003) 1.80
Fever episodes in a holoendemic malaria area of Tanzania: parasitological and clinical findings and diagnostic aspects related to malaria. Trans R Soc Trop Med Hyg (1993) 1.79
Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev (1989) 1.73
Agranulocytosis associated with malaria prophylaxis with Maloprim. Br Med J (Clin Res Ed) (1983) 1.72
The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol (1984) 1.65
Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health (1996) 1.65
Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther (2005) 1.59
Malaria chemoprophylaxis with mefloquine. Lancet (1991) 1.55
Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.54
Characterization of the humoral immune response in Plasmodium falciparum malaria. I. Estimation of antibodies to P. falciparum or human erythrocytes by means of microELISA. Clin Exp Immunol (1983) 1.54
Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci U S A (1986) 1.51
A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.50
Sensitive method for the determination of chloroquine and its metabolite desethyl-chloroquine in human plasma and urine by high-performance liquid chromatography. J Chromatogr (1980) 1.43
Chloroquine and desethylchloroquine concentrations during regular long-term malaria prophylaxis. Bull World Health Organ (1987) 1.43
Malaria prophylaxis policy for travellers from Europe to the Indian Subcontinent. Malar J (2006) 1.42
Anti-Plasmodium falciparum antibodies acquired by residents in a holoendemic area of Liberia during development of clinical immunity. Am J Trop Med Hyg (1986) 1.40
Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol (1996) 1.35
Sampling and storage of blood and the detection of malaria parasites by polymerase chain reaction. Trans R Soc Trop Med Hyg (1999) 1.34
On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther (1983) 1.34
Pneumocystis carinii pneumonia: detection of parasites in sputum and bronchoalveolar lavage fluid by monoclonal antibodies. BMJ (1988) 1.34
Synergism of benflumetol and artemether in Plasmodium falciparum. Am J Trop Med Hyg (1999) 1.33
Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol (1984) 1.32
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ (2003) 1.31
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and beta-thalassaemia traits. Ann Trop Med Parasitol (1983) 1.24
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.24
In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1991) 1.21
Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop (2006) 1.19
Determination of chloroquine and its metabolites in urine: a field method based on ion-pair extraction. Bull World Health Organ (1985) 1.19
Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop (1998) 1.19
Different malaria control activities in an area of Liberia--effects on malariometric parameters. Ann Trop Med Parasitol (1985) 1.19
Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol (2004) 1.18
Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J Pharm Biomed Anal (2005) 1.15
Lymphocyte activation and subset redistribution in the peripheral blood in acute malaria illness: distinct gammadelta+ T cell patterns in Plasmodium falciparum and P. vivax infections. Clin Exp Immunol (1997) 1.14
Falciparum malaria and beta-thalassaemia trait in northern Liberia. Ann Trop Med Parasitol (1983) 1.14
Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem (1994) 1.13
Long-term survival in transfusion recipients in Sweden, 1993. Transfusion (2001) 1.12
Human monoclonal antibodies to Pf 155, a major antigen of malaria parasite Plasmodium falciparum. Science (1986) 1.11
Parenteral chloroquine for treating falciparum malaria. J Infect Dis (1987) 1.09
High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics (1999) 1.09
A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J Pharm Biomed Anal (2005) 1.09
Acute psychosis following mefloquine prophylaxis. Lancet (1989) 1.05
Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia. Trans R Soc Trop Med Hyg (1999) 1.05
Characterization of the humoral immune response in Plasmodium falciparum malaria. III. Factors influencing the coexpression of antibody isotypes (IgM and IgG-1 to 4). Clin Exp Immunol (1986) 1.05
Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS (1999) 1.05
In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother (2002) 1.04
Higher proportion of CD8+ T cells in the blood in healthy adults from Ethiopia and Bangladesh compared with Sweden. Trans R Soc Trop Med Hyg (1998) 1.04
pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother (2012) 1.04
Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull World Health Organ (1989) 1.03
T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci U S A (1988) 1.03
In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. Br J Clin Pharmacol (1986) 1.03
Automated solid-phase extraction method for the determination of piperaquine in capillary blood applied onto sampling paper by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.01
Sulfadoxine assay using capillary blood samples dried on filter paper--suitable for monitoring of blood concentrations in the field. Ther Drug Monit (1987) 1.00
Lack of effect of desipramine on the response to chloroquine of patients with chloroquine-resistant falciparum malaria. Trans R Soc Trop Med Hyg (1992) 1.00
Efficacy of artemisinin and mefloquine combinations against Plasmodium falciparum. In vitro simulation of in vivo pharmacokinetics. Trop Med Int Health (1997) 0.99
Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab Dispos (2006) 0.99
Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg (1991) 0.98
Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J Chromatogr (1986) 0.98
Micronutrient and iron supplementation and effective antimalarial treatment synergistically improve childhood anaemia. Trop Med Int Health (2000) 0.98
Evaluation of three qualitative tests for detection of chloroquine in urine--agreement with plasma concentrations determined with liquid chromatography. Ann Trop Med Parasitol (1986) 0.98
Improved validated assay for the determination of mefloquine and its carboxy metabolite in plasma, serum and whole blood using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1999) 0.98
Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol (1998) 0.98
Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics (1999) 0.97
A study on malaria infection during the acute stage of measles infection. J Trop Med Hyg (1991) 0.97
Reliability of Dill-Glazko test. Lancet (1985) 0.97
Human monocytes cultured with and without interferon-gamma inhibit Plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. Parasite Immunol (1994) 0.97
Automated solid-phase extraction method for the determination of piperaquine in whole blood by rapid liquid chromatography. Ther Drug Monit (2003) 0.97
High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet (1997) 0.97
Regulation of the immune response in Plasmodium falciparum malaria: IV. T cell dependent production of immunoglobulin and anti-P. falciparum antibodies in vitro. Clin Exp Immunol (1987) 0.96
A longitudinal study of antibodies to the Plasmodium falciparum antigen Pf155/RESA and immunity to malaria infection in adult Liberians. Trans R Soc Trop Med Hyg (1991) 0.96
Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci (2008) 0.96
The seroreactivity against Pf155 (RESA) antigen in villagers from a mesoendemic area in Somalia. Trop Med Parasitol (1989) 0.95
Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand J Infect Dis (1994) 0.94
The effect of artemisinine, its derivatives and mefloquine against chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg (1992) 0.94
Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Bull World Health Organ (1994) 0.94
An improved gas chromatographic method for the simultaneous determination of chloroquine and two metabolites using capillary columns. J Chromatogr (1984) 0.94
Improved sensory relearning after nerve repair induced by selective temporary anaesthesia - a new concept in hand rehabilitation. J Hand Surg Br (2005) 0.93
Detection of asymptomatic Pneumocystis carinii infection by polymerase chain reaction: predictive for subsequent pneumonia. AIDS (1996) 0.93
The working capacity of Liberian males: a comparison between urban and rural populations in relation to malaria. Ann Trop Med Parasitol (1981) 0.92
Functional outcome thirty years after median and ulnar nerve repair in childhood and adolescence. J Bone Joint Surg Am (2013) 0.92
Field study of cyproheptadine/chloroquine synergism in falciparum malaria. Lancet (1990) 0.91
Simultaneous determination of pyrimethamine and sulphadoxine in human plasma by high-performance liquid chromatography. Trans R Soc Trop Med Hyg (1985) 0.91
A Plasmodium falciparum antigen containing clusters of asparagine residues. Proc Natl Acad Sci U S A (1986) 0.91
Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp Parasitol (2002) 0.91
No evidence of nosocomial Pneumocystis carinii infection via health care personnel. Scand J Infect Dis (1997) 0.90